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 ABSTRACT 
 
 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not 
Asenapine is more effective than other interventions in the treatment of adult patients with 
bipolar I disorder. 
 
STUDY DESIGN:  Review of three English language primary randomized controlled trial 
studies published from 2009-2010. 
 
DATA SOURCES:  Three randomized controlled trials studying the effectiveness of Asenapine 
in the treatment of mania in adult patients with bipolar I disorder in comparison to other 
interventions. 
 
OUTCOME MEASURED:  Outcomes measured were reduction in severity of manic symptoms 
and tolerability of the medication. The severity of manic symptoms was measured using the 
Young Mania Rating Scale (YMRS).  The YMRS is a self report questionnaire completed by the 
patients.  It includes rating scales for elevated mood, increased motor activity and energy, sexual 
interest, sleep, irritability, speech, language-thought disorder, content, disruptive-aggressive 
behavior, appearance, and insight.  Tolerability was based on adverse event assessment 
categorized in terms of maximum intensity and the investigator’s opinion of the relationship to 
the trial medication used.   
 
RESULTS:  The articles reviewed showed Asenapine was not more effective than Olazapine and 
had mixed results when compared to placebo. The McIntyre 2009 3 week study showed 
Asenapine to be superior to placebo in YMRS response. The McIntyre 2010 3 week study 
showed Asenapine to be nonsuperior over placebo and inferior to Olanzapine in YMRS 
response.  The McIntyre 2009 9 week extension study showed Asenapine to be noninferior to 
Olanzapine in YMRS response.  Asenapine was well tolerated. 
 
CONCLUSIONS:  Based on the articles reviewed, it is unclear how effective Asenapine is in 
YMRS response rates.  It may be a potential option for the treatment of mania in patients 
diagnosed with bipolar I disorder, but more research is needed.  
 
KEY WORDS: Asenapine; Bipolar I Disorder; Olanzapine; Mania; Mixed state 
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INTRODUCTION  
 
Bipolar I disorder, bipolar II disorder, and cyclothymic disorder all make up the broader 
spectrum known as bipolar disorder, a common and serious mental health condition.1   Bipolar I 
disorder, specifically, consists of episodes of mania cycling with depression that most often 
begin quickly and escalate rapidly.  An episode of mania is typically defined as an abnormally 
and continuously elevated, expansive, or irritable mood.1  The impact can be devastating to the 
patient’s physical and psychosocial health often interfering with occupational and social 
functioning and commonly leading to hospitalization.  In fact, it is estimated that patients with 
bipolar disorder have suicide rates 2-3 times higher than that of the general population.1 The 
etiology is unknown and there are no diagnostic tests or lab studies specific for a diagnosis of 
bipolar disorder.  However, some risk factors have been identified.  Key risk factors for bipolar 
disorder include female sex, family history of the disorder, and upper socioeconomic class.   
It is estimated that bipolar disorder affects over three million people in the United States 
and accounts for one quarter of all mood disorders.1  The lifetime prevalence is believed to be as 
high as 4%.2  Therefore, bipolar disorders cross over into many scopes of PA practice and it is 
important for practitioners to be able to recognize the condition and provide proper treatment.  
Although there is no national database identifying how many healthcare visits each year occur 
due to bipolar disorder, it is estimated that $45 billion are spent annually on the disorder, making 
it the most costly behavioral health condition in the United States.3,4   
There is no cure for bipolar I disorder.  Treatment entails management of acute episodes 
as well as maintenance therapy.  Manic episodes can be managed acutely with either lithium or 
atypical antipsychotics.   Atypical antipsychotics work by blocking dopamine pathways in the 
brain.  General side effects include blood clotting, tardive dyskinesia, significant weight gain, 
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and metabolic syndrome.  Consequently, insufficient tolerability has contributed to high rates of 
nonadherence to treatment.  Asenapine, a newer atypical antipsychotic, gained FDA approval in 
2009 for the treatment of mania or mixed episodes associated with bipolar I disorder.   It is 
formulated as a quick dissolving sublingual tablet that is rapidly absorbed with peak plasma 
concentrations occurring about one hour after administration.  Current research is hopeful that 
Asenapine will prove to be a superior option in both efficacy and tolerability over other available 
treatments. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “Is Asenapine 
more effective than other interventions in the treatment of adult patients with bipolar I disorder?”   
METHODS 
 A detailed search was completed by the author using the key words Asenapine, 
Olanzapine, bipolar I disorder, mania, and mixed state.  The search engines used were OVID, 
Medline, and PubMed and the articles selected were published in English and in peer-reviewed 
journals from 2009-2010.  Each article focused on outcomes that were of importance to the 
patient (Patient Oriented Evidence that Matters, or POEMS).  Randomized controlled trails 
(RCTs) were searched for the following inclusion criteria: patient population 18 years old or 
greater with a diagnosis of bipolar I disorder and experiencing manic or mixed episodes.  Three 
studies, all randomized clinical trials, were chosen comparing Asenapine to Olanzapine and/or 
placebo in the treatment of mania in adult patients with bipolar I disorder.  Of these studies, two 
were double blind placebo-controlled, and the other was a double blind placebo-controlled 
extension study.  Variable dosing of Asenapine and Olanzapine was incorporated into each 
study.  Excluded studies were those that used Asenapine as treatment for conditions other than 
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bipolar I disorder.  Table 1 demonstrates the demographics of the studies included.  Each study 
reported statistics based on severity of manic symptoms as rated by the patient.  Statistics were 
reported using p-values, 95% confidence intervals (CI), relative benefit increase (RBI), absolute 
benefit increase (ABI), relative risk increase (RRI), absolute risk increase (ARI), number needed 
to treat (NNT), and number needed to harm (NNH). 
OUTCOMES MEASURED 
 Outcomes measured in all of the studies included the improvement of mania severity as 
reported by the patient using the Young Mania Rating Scale (YMRS).  The YMRS is self report 
questionnaire in which the patient rates their symptom severity in 11 different categories.  These 
categories include elevated mood, increased motor activity and energy, sexual interest, sleep, 
irritability, speech, language-thought disorder, content, disruptive-aggressive behavior, 
appearance, and insight.  Symptom severity, especially in these categories, is important to the 
patient; thus qualifying this outcome as a POEM.  The YMRS score ranges from 0-60.  Clinical 
severity categories based on YMRS total score are mild (15-20), moderate (21-28), and severe 
(29-44).  This paper evaluates the percentage of YMRS responders, which is defined as those 
experiencing greater than a 50% decrease from their baseline YMRS score upon completion of 
the trial medication. 
 Another outcome measured was tolerability to the medications used.  This was evaluated 
by adverse events which were categorized based on level of intensity and the investigator’s 
opinion on the relationship of the adverse event to the trial medication used.  Vital signs were 
assessed at each visit.  Additionally, blood samples, urinalysis, electrocardiograms, body weight, 
and metabolic indices were assessed throughout the trial.  This paper evaluates those adverse 
events labeled as a serious adverse event, or SAE.   
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Table 1: Demographics and characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
McIntyre 
 
RCT 488 18-
65+; 
mean 
age of 
39.4 
Primary Dx of 
bipolar I 
disorder; 
YMRS > 20; 
current manic/ 
mixed episode 
(< 3 mo ago); 
history of 1 or 
more moderate 
to severe 
episodes 
Seizures; HIV+; 
Rapid-cycling; 
substance abuse or 
dependence; positive 
stimulant screen; 
pregnant or may 
become pregnant; 
use of clozapine 
within 12wks; 
previous trial 
enrollment; 
hypersensitivity to 
meds used; 
neuroleptic 
malignant syndrome 
152 
 
Asenapine 
SL (10 mg 
BID day one, 
5 or 10 mg 
BID 
thereafter); 
Oral 
olanzapine 
(15 mg QD 
on day one, 
5, 10,15, 20 
mg QD 
thereafter); 
matched 
placebo 
McIntyre  RCT 488 18-
65+; 
mean 
age of 
38.6 
Primary 
diagnosis of 
bipolar I 
disorder; 
YMRS > 20; 
current manic/ 
mixed episode 
(< 3 mo ago); 
history of 1 or 
more moderate 
to severe 
episodes 
Seizures; HIV+; 
Rapid-cycling; 
substance abuse or 
dependence; positive 
stimulant screen; 
pregnant or may 
become pregnant; 
use of clozapine 
within 12wks; 
previous trial 
enrollment; 
hypersensitivity to 
meds used; 
neuroleptic 
malignant syndrome 
146 Asenapine 
SL (10 mg 
BID day one, 
5 or 10 mg 
BID 
thereafter); 
Oral 
olanzapine 
(15 mg QD 
on day one, 
5,10,15, or 
20 mg QD 
thereafter; 
matched 
placebo 
McIntyre  RCT 504 18-73 >18 years old 
with bipolar I 
disorder; 
experiencing 
manic/mixed 
episodes; 
completed a 
previous 3 
week trial; 
continued 
treatment 
could be of 
clinical benefit 
Did not complete 
previous 3 week 
trial; rapid cycling 
mood course; 
substance abuse or 
dependence; 
imminent risk of 
harm to self or 
others; unlikely to 
comply 
195 Asenapine 
SL (10 mg 
BID on day 
one, 5 or 10 
mg BID 
thereafter); 
Oral 
olanzapine 
(15 mg QD 
day one, 
5,10,15,20 
mg QD 
thereafter)  
Asenapine and Bipolar I Disorder, Tsakiris 5 
 
RESULTS 
This EBM review was done on three randomized controlled trials; two of which were 
three week comparative trials, and the other a nine week extension study.  Each article used 
dichotomous data when presenting outcomes.  The dosing of medications was the same in each 
trial study.  The dosing was as follows: sublingual Asenapine (10 mg BID on day 1, followed by 
5 or 10 mg BID thereafter) and oral Olanzapine (15 mg BID on day 1, followed by 5, 10, 15, or 
20 mg QD thereafter).  Visually matched placebo was incorporated into both 3 weeks studies, 
but it was not included in the 9 week extension study.  The primary efficacy measured in all of 
the studies was the change in the YMRS score.  This review focuses on YMRS responders which 
are defined as those having a > 50% reduction from baseline YMRS score at study endpoint.  All 
patients that participated in the study had a primary diagnosis of bipolar I disorder and were 
currently experiencing manic or mixed episodes.  All patients were 18 years of age or older.   
It is important to understand the statistical calculations that were used to evaluate the 
articles selected.   The percentage of YMRS responders was considered for the efficacy rate for 
each intervention, with Asenapine being the Experimental Event Rate (EER) and Olanzapine or 
placebo being the Controlled Event Rate (CER).  The EER and CER can be used to calculate the 
Relative Benefit Increase (RBI) and Absolute Benefit Increase (ABI).  The ABI, which is the 
absolute arithmetic difference in rates of good outcomes between the experimental and control 
groups, can then be used to calculate the Numbers Needed to Treat (NNT).  The NNT tells the 
practitioner the number of patients that need to be treated in order to obtain one additional good 
outcome as compared to the control medication.     
In the McIntyre, 2009 three week study, 488 patients with a mean age of 39.4 years old 
enrolled in the study.2  The YMRS score was assessed at baseline, days 2, 4, 7, 14, and study 
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endpoint (day 21).  In order to qualify for the study, patients had to have a baseline YMRS score 
> 20.  Trial completion rates were 62.9%, 61.5%, and 79.6% for Asenapine-, placebo-, and 
Olanzapine-treated patients, respectively. YMRS response was analyzed using Pearson chi-
square tests, with last observation carried forward (LOCF).  All participants were randomly 
allocated into either an experimental group (Asenapine) or a control group (Olanzapine or 
placebo).  The percentage of YMRS responders for Asenapine versus placebo were 42.3% and 
25.2%, respectively.  Asenapine showed a greater response over placebo, and the data is 
considered clinically significant with a p-value < 0.01.  The NNT calculated for Asenapine 
versus placebo was 6 (95% CI: 3 to 17).  The percentage of YMRS responders for Asenapine 
versus Olanzapine were 42.3% and 50.0%, respectively, and the NNT value was -13.  However, 
the trial included Olanzapine as a way to assess assay sensitivity in the event that outcomes 
measured between Asenapine and placebo were not significantly different.  Therefore, no p-
value or 95% CI was available comparing Asenapine and Olanzapine.  The results are 
summarized in Table 2 and Table 3. 
In the McIntyre, 2010 three week study, 488 patients with a mean age of 38.6 years old 
enrolled in the study.3   This study shared many of the same characteristics as the McIntyre 2009 
three week study, such as required baseline YMRS > 20, YMRS responder analysis using 
Pearson chi-square tests and LOCF, and Olanzapine included to assess assay sensitivity.  
However, this study performed a post hoc analysis comparing YMRS response rates for 
Asenapine and Olanzapine on day 21.  Trial completion rates were 67.0%, 58.2%, and 78.5% for 
Asenapine-, placebo-, and Olanzapine-treated patients, respectively.  The percentage of YMRS 
responders for Asenapine versus placebo were 42.6% and 34.0%, respectively.  Asenapine did 
not significantly differ from placebo (p-value > 0.05), and the NNT is 12 (95% CI: -∞ to -29 and 
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4 to ∞).  The percentage of YMRS responders for Asenapine versus Olanzapine were 42.6% and 
54.7%, respectively, and the NNT value was -9.  Post hoc analysis showed YMRS response rates 
with Olanzapine to be significantly greater than those with Asenapine (p-value < 0.05).  The 
results are summarized in Table 2 and Table 3. 
In the McIntyre, 2009 nine week extension study, Asenapine and Olanzapine were 
directly compared.4  Completion of a prior three week trial was required to participate in the 
additional nine week extension study.  Upon initiation of the trial, there was no rerandomization 
or identification of prior treatment groups.  Those receiving placebo were blindly switched to 
Asenapine, but were only included in the safety analysis.   A total of 504 patients enrolled in the 
trial, and completion rates were 62%, 53%, and 64% for Asenapine-, placebo/Asenapine-, and 
Olanzapine-treated patients, respectively.  YMRS response rates at day 84 were 90% and 92% 
with Asenapine and Olanzapine, respectively.   These rates are not significantly different (p-
value >0.05), and the NNT is -50.  The results are summarized in Table 3. 
 
Table 2: Asenapine vs. Placebo on YMRS response 
 Asenapine 
(EER) 
Placebo 
(CER) 
p-value RBI ABI NNT 
McIntyre, 
2009 (3 
weeks) 
 
42.3% 
 
25.2% 
 
<0.01 
 
0.68 
 
0.171 
 
6a 
McIntyre, 
2010 (3 
weeks) 
 
42.6% 
 
34.0% 
 
>0.05 
 
0.25 
 
0.086 
 
12b 
a 95% CI: 3 to 17  
b 95% CI: -∞ to -29 and 4 to ∞ 
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Table 3: Asenapine vs. Olanzapine on YMRS response  
 Asenapine 
(EER) 
Olanzapine  
(CER) 
p-value RBI ABI NNT 
McIntyre, 
2009 (3 
weeks) 
 
42.3% 
 
50.0% 
 
NA 
 
-0.15 
 
-0.077 
 
-13 
McIntyre, 
2010 (3 
weeks) 
 
42.6% 
 
54.7% 
 
<0.05a 
 
-0.26 
 
-0.120 
 
-9 
McIntyre, 
2009 (9 
week 
extension) 
 
92.0% 
 
90.0% 
 
>0.05 
 
-0.02 
 
-0.020 
 
-50 
a based on post hoc analysis conducted at day 21 
 
 This review also looked at safety and tolerability outcomes as measured by the 
percentage of treatment-emergent serious adverse events, or SAE.  All three trials reviewed in 
this paper provided percentages of SAE, and these values were used to calculate relative and 
absolute risk increases (RRI and ARI), which in turn are used to calculate the Number Needed to 
Harm (NNH).  The NNH can tell a practitioner how many patients can be treated with the 
experimental treatment over the control treatment before one patient will be harmed.  Table 4 
and Table 5 summarize the safety and tolerability data from the articles reviewed.  There were 
no p-values or CI values available for this data. 
 
Table 4: Serious Adverse Event Data for Asenapine vs. Placebo 
 Asenapine 
(EER) 
Placebo  
(CER) 
RRI ARI NNH 
McIntyre, 
2009 (3 
weeks) 
 
4.10% 
 
6.70% 
 
-0.39 
 
-0.026 
 
-37 
McIntyre, 
2010 (3 
weeks) 
 
6.50% 
 
7.10% 
 
-0.08 
 
-0.006 
 
-167 
 
 
 
 
Asenapine and Bipolar I Disorder, Tsakiris 9 
 
Table 5: Serious Adverse Event Data for Asenapine vs. Olanzapine  
 Asenapine 
(EER) 
Olanzapine  
(CER) 
RRI ARI NNH 
McIntyre, 
2009 (3 
weeks) 
 
4.10% 
 
3.71% 
 
0.66 
 
0.004 
 
250 
McIntyre, 
2010 (3 
weeks) 
 
6.50% 
 
3.90% 
 
0.66 
 
0.026 
 
39 
McIntyre, 
2009 (9 week 
extension) 
 
12.0% 
 
10.0% 
 
0.20 
 
0.020 
 
50 
 
DISCUSSION 
 Atypical antipsychotics have proven to be effective in the treatment of mania in bipolar 
patients, and their use in practice has increased considerably.  Asenapine (Saphris®) is a newer 
atypical antipsychotic which gained FDA approval in 2009.  It is approved in the United States 
for use in both schizophrenia and acute mania associated with bipolar disorder.   The FDA issued 
a black box warning for elderly patients with dementia-related psychosis due to increase risk of 
stroke or death with Asenapine.  Research is currently underway to determine how effective and 
tolerable Asenapine will be compared to other atypical antipsychotics and other treatment 
options.  
The randomized controlled trials in this review demonstrated mixed results in terms of 
efficacy rates for Asenapine versus Olanzapine or placebo, and it is clear that additional research 
is needed to determine how effective Asenapine may be in the treatment of mania in bipolar 
patients. 
The studies used in this review were not without limitations.  In patients with bipolar 
disorder, nonadherence to treatment and concomitant medication use are significant concerns and 
can complicate trial results.   The duration of the studies used in this review ranged from three 
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weeks to twelve weeks which is not an adequate amount of time to influence clinical decision 
making for a chronic mental health condition such as bipolar disorder.   Additionally, the 
outcome used to measure efficacy (YMRS response) was assessed at one single point in time 
limiting the interpretation of data.  In both three week trials, Olanzapine was used to assess assay 
sensitivity; therefore, comparisons between Olanzapine and Asenapine need to be interpreted 
with caution.2,3   
CONCLUSION 
 The studies reviewed show that Asenapine is not more effective than Olanzapine, and the 
results were mixed regarding superiority of Asenapine over placebo.  Asenapine may be an 
effective and tolerable option for treating mania in bipolar patients; although, the varying results 
in each article indicate more research is needed to establish more certain efficacy rates.   The 
2009 3-week study showed Asenapine to be superior to placebo.  The 2010 3-week study showed 
that Asenapine was not clinically superior to placebo in YMRS response; however, the primary 
outcome measured in this article (least squares mean changes in YMRS score) did show 
superiority with Asenapine.  The 2009, 9 week extension study had the longest duration and 
perhaps the most promising results for Asenapine which was found to be noninferior to 
Olanzapine and well tolerated.  None of the studies included in this review proved Asenapine to 
be superior over Olanzapine in efficacy.    
It is important to remember that bipolar I disorder is a chronic condition that typically 
requires lifelong therapy.  Longer duration studies are needed to help understand the role 
Asenapine may play in treatment.  Asenapine is a relatively new drug (FDA approved in 2009) 
and limited studies have been published to date regarding its use in bipolar disorder.  Studies that 
utilize a more controlled setting that would limit concomitant medication use and nonadherence 
Asenapine and Bipolar I Disorder, Tsakiris 11 
 
to treatment would be beneficial.  Additionally, incorporating patients experiencing rapid cycling 
bipolar disorder could provide insight since these patients typically have a more refractory 
course of illness.  Another point of interest that is worth reviewing is route of administration.  
Asenapine was developed as a sublingual tablet which could be beneficial to those with manic 
episodes having trouble swallowing medication.   
In conclusion, the articles in this review had mixed results regarding the efficacy rates of 
Asenapine as measured by YMRS response.  More research is needed to clarify how to 
incorporate Asenapine into the clinical management of bipolar I patients experiencing manic 
episodes.     
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